Brief: Aequus Announces Sandoz Contract Expiry At Year End And Expected Health Canada Approval For Zimed® Pf (Preservative Free)
29/11/2022 13:10
Nov 29 (Reuters) - Aequus Pharmaceuticals Inc AQS.V :
* AEQUUS ANNOUNCES SANDOZ CONTRACT EXPIRY AT YEAR END AND
EXPECTED
HEALTH CANADA APPROVAL FOR ZIMED® PF (PRESERVATIVE FREE)
* AEQUUS PHARMACEUTICALS - AGREED TO END PROMOTIONAL SERVICE
AGREEMENT WITH SANDOZ CANADA ON TACROLIMUS IR AND VISTITAN
EFFECTIVE DECEMBER 31, 2022
* AEQUUS PHARMACEUTICALS INC - HEALTH CANADA APPROVAL IS
EXPECTED
BEFORE YEAR END 2022
Source text for Eikon: ID:nGNX8T18R1
Further company coverage: AQS.V
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aequus Pharmaceuticals
See all newsBrief: Aequus Pharmaceutical Canada Pauses Sales Of Evolve Intensive Eyedrops, Gel In Canada
Brief: Aequus Announces Financing To Support Launch Of Zimed Preservative Free (Bimatoprost 0.03%) And Board Update
Brief: Aequus Announces Health Canada Notice Of Compliance For Zimed® Preservative Free
Brief: Aequus Announces Sandoz Contract Expiry At Year End And Expected Health Canada Approval For Zimed® Pf (Preservative Free)
Brief: Aequus Resumes Trading On TSX Venture Exchange